Print

Year-end Report January - December 2011

2012-02-16

·Laquinimod- a clinical trial is planned prior to filing an NDA in the US

·TASQ- an investigator-sponsored Phase I clinical trial launched
- enrolment of patients for Phase III trial proceeding according to plan

·ANYARA- Phase III trial continuing according to plan

·57-57 - a clinical trial in systemic sclerosis/scleroderma initiated

·ISI- project is proceeding as planned

·RhuDex®- a Phase I clinical formulation study launched

·Focusing of the operation; notice of termination of employment to 25 staff members

·Net sales SEK 234.6 M (11.4)

·Operating loss SEK 100.9 M (Loss: 229.0)

·Loss after tax SEK 94,5 M (Loss: 221.1)

·Loss per share for the period was SEK 1.38 (Loss: 3.38)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95

Hans Kolam
CFO
Tel +46 (0)46-19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


pdfYear-end Report January - December 2011



Back